Academic literature on the topic 'Korea Chemical Company'

Objectives:According to the material flow analysis, the domestic flow of trichloroethylene with the highest emission among carcinogens in group 1 was determined. The purpose of this study is to provide basic data for efficient chemical management and establish measures to reduce emissions.Methods:In this study, the material flow analysis of trichloroethylene was analyzed in Korea in 2014. The material flow chart was presented using STAN 2.6 software. The flow of trichloroethylene by region and industry was analyzed to identify the characteristics of each flow, and the emission reduction method was presented.Results and Discussion:Trichloroethylene was used up to 79.8% in the Seoul metropolitan area, 45.6% in the manufacturing of other machinery and equipment, and 29.4% in the manufacturing of fabricated metal products except machinery and furniture. Trichloroethylene was emitted 42.0% in the manufacturing of rubber and plastics products and 26.8% in the manufacturing of primary metals. The analysis of emissions by company size resulted in 3.9% of total emissions from large companies, 61.6% from mid-sized companies, and 34.5% from small-sized companies. Trichloroethylene was used in various industries and regions, with higher emissions compared to its use.Conclusions:Trichloroethylene has been emitted in large quantities relative to its usage. The study found that the management of chemicals in small businesses was insufficient. This result of the material flow analysis is used as basic data to reduce emissions of chemicals. The result of the study helps to recognize the risk of chemicals and suggest alternative materials, introduce inter-company information and expert exchange system, introduce a total amount of carcinogens emission system, implement duties in the emission reduction plan, and consider emission reduction incentives. In addition, measures to improve risk are proposed to establish risk-based database.

In 2004 and 2005 GE invested about 1.3b USD in Hyundai Card and Hyundai Capital in a deal that saw them become the 2nd largest shareholder of each company. At that time, the two Hyundai-owned companies had been significantly affected by the credit card crisis in Korea and both were in dire need of capital in order to normalize their operations. After forming a joint venture with GE, Hyundai Card and Hyundai Capital experienced a cultural clash between GE’s principle-oriented culture and Hyundai’s speed-orientated culture. Nevertheless, Hyundai Card and Hyundai Capital overcame these difficulties and created synergetic processes in a way that sees it defined as being one of GE’s most successful foreign joint venture cases. The joint venture between GE and Hyundai is not just simply a combination of financial assets, it is a tight bond that reflects the chemical fusion that can exist between corporate culture and people.

This study aims to analyze the engineering properties of cementless grouting materials (CGMs) and derive optimal binder types and compositions that can ensure superior material performance in comparison with ordinary Portland cement (OPC). The presented CGM is an environment-friendly inorganic binder based on ground granulated blast-furnace slag. The material properties of three CGM types with different chemical compositions were evaluated. To assess the possibility of using CGMs in grouting-construction methods, this study followed special grouting-method specifications of the J company in Korea, and tested whether CGM satisfies the performance requirements of a gel time of 20–50 s and homogel strength greater than 2 MPa after 7 days. For OPC and CGM, gel time increased and homogel strength decreased as the water/binder (W/B) ratio of Liquid B increased or as its replacement ratio decreased. Additionally, gel time decreased while homogel strength increased as the absolute weight of the Liquid B binder increased, and a negative correlation was observed between gel time and homogel strength. CGM2 was the optimal binder to ensure excellent material performance compared with OPC. Optimal mixing proportions were 117.8–167.7% W/B ratio, 42.6–56.7% Liquid B volume ratio, and 20.4–43.7 kg binder weight.

Justicia procumbens L. is known across Korea, India, China, and Taiwan as a remedy against fever, cough, sore throat, and cirrhosis of ascites. J. procumbens provides the raw material for a candidate anti-asthma drug (DW2008S) currently completing phase I clinical trials sponsored by Dong Wha Pharmaceutical Company. HPLC-DAD was used to quantify phytochemical constituents of J. procumbens, and HPLC and 1H-NMR results were assessed by multivariate analysis. This is the first time a comparative study using HPLC-DAD and NMR fingerprints has been applied to identify chemical differences between wild and cultivated J. procumbens. The amount of justicidin B as the marker compound was higher in cultivated samples (0.80 ± 0.25 mg/g) than in wild ones (0.63 ± 0.30 mg/g). Orthogonal partial least squares discriminant analysis (OPLS-DA) from HPLC and NMR data revealed that there were clear differences between wild and cultivated types and identified five secondary metabolites, which could help distinguish between wild and cultivated plants. Among these five lignans, diphyllin showed the most potent discrimination between two types and was significantly detected higher in cultivated ones than in wild ones. A combination of 1H-NMR and HPLC-DAD analysis is effective for J. procumbens standardization and metabolomics studies.

This study examined the potential reuse of powdered wastes (PW) generated during the sanding and sawing process in a local chemical company in Korea with the viewpoint of the recycling these wastes and minimizing the level of contamination. As the aluminium hydroxide inside the PW could be thermally converted to various types of aluminium oxides depending on the calcination temperature, the adsorptive properties could be changed and it may affect on adsorption ability. Calcination of the PW was performed for 3 h at 550°C, 750°C, and 950°C. From the results, amorphous aluminium oxide was thermally generated by calcinating the PW at 550°C and with further increase of temperature to 950°C, the crystallinity of amorphous aluminium oxide was gradually increased. The physicochemical analysis of calcined powdered wastes (CPW) at various temperatures showed that more developed porosity was noted in the CPW as the calcinations temperature increased, whereas surface area was significantly decreased from 175.5 m2 g−1 to 46.5 m2 g−1. The removal efficiency of arsenate on the CPW decreased as the calcinations temperature increased from 550°C to 950°C. The CPW550 exhibited the highest adsorption capacities toward arsenate over pH range of 2–8 and showed a complete removal of the arsenate (10.0 mg L−1) within the first 10 min. Adsorption kinetic studies showed that the rate of arsenic adsorption on the CPW decreased with the increase of the calcination temperature. When the maximum adsorption capacity of arsenic onto the CPW was calculated by Langmuir equation, the CPW550 has the highest value as 43.9 mg g−1.

Oil and petrochemical companies are in the severe situation where they shoulddeal with various problems. In Europe, America, the Middle East, and East Asia (China, Taiwan,and South Korea), one company usually builds a large-scale factory, and consistently producesoil and petrochemical goods in the system of one company. Differently from it, two or morecompanies are concentrated in the coast landfills in Japan, and generally manufacture in thesystem of groups. The system of production in a petrochemical complex would be a mediumscalelevel if it sees worldwide. After World War II, capital was insufficient in Japan. Manycompanies advanced to the oil and petrochemical industry which seemed to have a big future.Small and medium scale factories were constructed. As a result, petrochemical complexeshave been formed with the system of groups.After the defeat of World War II, many oil companies excluding Idemitsu Kosan Co., Ltd. wereorganized for the supply of crude oil from European and American oil majors. They weredevoted to refining oil and selling it only in Japan. Moreover, the oil market in Japan had beendefended by restriction of the government. Such a system continued for years. Therefore,domestic oil companies had been aiming at improvement and efficiency of refining capacity.Their concentrating on technological development, cost reduction, and domestic share foughtin the same industry had become a main activity. The construction of global competitiveness hadbeen postponed for a while. However, after repealing protected laws, the import liberalizationof petroleum product had been taken since 1996, and cheap petroleum products had flown infrom foreign countries. The sales price had not become the same, and free competition undermarket mechanism had started. As a result, the movement of industry reorganization hadbeen accelerated.In such a severe situation, oil and petrochemical companies came up with the idea of businesscooperation in the same region in order to acquire global competitiveness. 20 companies inoil industry and chemical industry gathered round at first. Under the Research Associationof Technology Law, Research Association of Refinery Integration for Group-Operation (RING)was established in 2000. In order to gain global competitiveness, RING has acted groupoperationprograms in the industrial complexes in Japan. In this paper, I describe the historicalformation and development of petrochemical complexes in Japan.And I consider and analyzethe approach to and ways of the high-level integration for group operation. And I will explainthe meaning of the plans, and the economies arising from the group operation business.

The cyclic ether 1,4-dioxane is a synthetic industrial chemical that is used as a solvent in producing paints and lacquers. The EPA and the International Agency for Research on Cancer(IARC) classified 1,4-dioxane as a GROUP B2(probable human) carcinogen. 1,4-dioxane is also produced as a by-product during the manufacture of polyester. In this research, a polyester manufacturing company (i.e. K Co.) in Gumi, Korea was investigated regarding the release of high concentrations of 1,4-dioxane (about 600 mg/L) and whether treatment prior to release should occur to meet with the level of the regulation standard (e.g., 5 mg/L in 2010). A 10 ton/day pilot-scale treatment system using photo-Fenton oxidation was able to remove approximately 90% of 1,4-dioxane under the conditions that concentrations of 2800 ppm H2O2 and 1,400 ppm FeSO4 were maintained along with 10 UV-C lamps (240 μW/cm2) installed and operated continuously during aeration. However, the effluent concentration of 1,4-dioxane was still high at about 60 mg/L where TOC concentration in the effluent had been moreover increased due to decomposed products such as aldehydes and organic acids. Thus, further investigation is needed to see whether the bench scale (reactor volume, 8.9 L) of activated sludge could facilitate the decomposition of 1,4-dioxane and their by-products (i.e., TOC). As a result, 1,4-dioxane in the effluent has been decreased as low as 0.5 mg/L. The optimal conditions for the activated sludge process that were obtained are as follows: DO, 3-3.5 mg/L; HRT, 24 h; SRT 15 d; MLSS, 3,000 mg/L. Consequently, photo-Fenton oxidation coupled with activated sludge can make it possible to efficiently decompose 1,4-dioxane to keep up with that of the regulation standard.

PT. Inkomas Lestari is the first and only producer from Indonesia to produce tin chemicals and polymer additives. The products produced by PT. Inkomas Lestari is not only able to meet the needs of the local market, but also meet the needs of the international market by exporting its products to Germany, Korea, China and several countries in the Asian region. However, based on the results of the evaluation conducted by researchers, PT. Inkomas Lestari is known to not optimize its inventory management, in which the company does not keep stock of raw material inventory in the warehouse, so that it often experiences an increase in inventory costs. This research was conducted with the aim of reducing inventory costs by calculating the safety stock needed by the company using the Economic Order Quantity (EOQ) method. Based on the calculation results, it is known that PT. Inkomas Lestari with the EOQ method obtained a total inventory cost of Rp. 1,888,637,963 which is lower than the company using the conventional method which has to pay Rp. 2,112,320,822, then with a difference in total inventory cost of Rp. 223,682,857. This means that the Economic Order Quantity (EOQ) method can be considered more efficient than the conventional method currently being applied by the company.

Abstract Background: Darinaparsin is a novel organic arsenic compound composed of dimethylated arsenic linked to glutathione. In two phase I studies including Japanese and Korean patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), darinaparsin was well tolerated and demonstrated potential efficacy (ASH2015 Abstract #2714 and Jpn J Clin Oncol. 2021, 51:218). The efficacy, safety and pharmacokinetics of darinaparsin in Asian patients with relapsed or refractory PTCL were evaluated in a multinational phase II study. Methods: Eligible patients had histologically confirmed PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) or anaplastic large cell lymphoma (ALCL), which had relapsed from or were refractory to one or more prior regimen with systemic chemotherapy. Darinaparsin was intravenously administered for 5 consecutive days at 300 mg/m 2/day every 3 weeks. The primary endpoint was the overall response rate (ORR) within 6 cycles of treatment. Tumor response was assessed based on computed tomography (CT) and fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation by central review according to the Revised Response Criteria for Malignant Lymphoma (J Clin Oncol. 2007, 25:579). Secondary endpoints included progression-free survival (PFS), overall survival (OS), toxicity, and pharmacokinetic parameter. This study was conducted in 25 sites in East Asia (13 in Japan, 6 in Korea, 5 in Taiwan, and 1 in Hong Kong). Results: A total of 65 patients (37, 19, 8 and 1 from Japan, Korea, Taiwan and Hong Kong, respectively) including 43 PTCL-NOS, 17 AITL and 3 ALK-negative ALCL; 45 males and 20 females, with a median age of 68 (range 28-85) years received darinaparsin. The median number of prior systemic chemotherapy regimens was 2 (range 1-11). Approximately 30% of patients did not have evidence of response to the most recent prior systemic therapy. The median number of cycles received darinaparsin was 3 (range 1-39). In 57 evaluable patients, the ORR as assessed by an independent efficacy assessment committee was 19% (11 of 57; 90% Confidence Interval (CI) 11.2-29.9), and the lower limit of the 90% CI exceeded the predefined 10% threshold (p=0.024, binomial test). The ORR was 16.2% (6 of 37) in the subjects with PTCL-NOS and 29.4% (5 of 17) in the subjects with AITL. None of the subjects with ALCL, ALK-negative responded. Of the 11 responders, 5 achieved a Complete Response (CR) (8.8%), and 6 had a Partial Response (PR) (10.5%). Eight of the 11 responders showed response by Cycle 3. The disease control rate defined as the proportion of patients who achieved CR, PR or Stable Disease (SD) was 46% (26 of 57, 90% CI 34.3-57.3), and more than half of the patients achieved tumor shrinkage (Figure 1). Median duration of response (DOR) was 3.8 months (90% CI 2.7-5.7). Four patients who had achieved SD or better continued the treatment with darinaparsin for more than 1 year, and median duration of treatment in these subjects was 28.6 months (range 14-41). Median PFS and OS were 3.3 months (90% CI 1.9-4.2) and 13.7 months (90% CI 9.9-18.6), respectively. Among all 65 treated patients, the incidence of adverse events (AEs) was 97%, and that of drug-related AEs was 68%. AEs with an incidence of ≥ 20% were pyrexia (42%), anemia (25%), thrombocytopenia (20%) and decreased appetite (20%). The incidence of ≥ Grade 3 AEs was 62%, and that of ≥ Grade 3 drug-related AEs was 29%. The common ≥ Grade 3 AEs were anemia (15%), thrombocytopenia (12%), neutropenia (12%), lymphopenia (9%) and leukopenia (9%). While electrocardiogram (ECG) QT prolongation at 3% was reported as drug-related AEs associated with cardiac toxicity, there were no substantial changes from baseline in the descriptive statistics of ECG parameters associated with darinaparsin treatment. There was no apparent ethnic difference in pharmacokinetic profiles of patients studied. Conclusions: Darinaparsin had clinical efficacy and was well tolerated in patients with relapsed or refractory PTCL. AEs were clinically acceptable and manageable. Darinaparsin is a potential option for the treatment of relapsed or refractory PTCL. Updated results of DOR PFS, OS, and long-term safety are being analyzed for presentation at the conference. Figure 1 Figure 1. Disclosures Fukuhara: Ono Pharmaceutical: Honoraria, Research Funding; Novartis: Honoraria; Nippon Shinyaku: Honoraria; Kyowa Kirin: Honoraria; Janssen: Honoraria; Incyte: Research Funding; HUYA Bioscience International: Honoraria; Eisai: Honoraria; Chugai Pharmaceutical: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Bayer: Research Funding; AbbVie: Honoraria; Takeda Pharmaceutical: Honoraria; Zenyaku Kogyo: Honoraria. Kim: Celltrion: Research Funding; Dong-A Pharmaceutical: Research Funding; Eisai: Research Funding; Johnson & Johnson: Research Funding; Kyowa Kirin: Research Funding; Roche: Research Funding; IGM Biosciences: Research Funding; Sanofi: Research Funding. Yamamoto: Nippon Shinyaku: Honoraria, Research Funding; Otsuka: Honoraria, Research Funding; Ono: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Sanofi: Honoraria; Solasia Pharma: Research Funding; SymBio: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Yakult: Honoraria, Research Funding; Zenyaku: Honoraria, Research Funding; Micron: Honoraria; IQIVA/Genmab: Research Funding; ADC Therapeutics: Honoraria; Chugai: Honoraria, Research Funding; Daiichi Sankyo: Honoraria; Eisai: Honoraria, Research Funding; IQIVA/Incyte: Research Funding; IQIVA/HUYA: Honoraria; HUYA: Consultancy; Janssen: Honoraria; Kyowa Kirin: Honoraria; Meiji Seika Pharma: Consultancy, Honoraria, Research Funding; MSD: Honoraria; Mundipharma: Research Funding; Bristol-Myers Squibb/Celgene: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding. Izutsu: Novartis: Honoraria, Research Funding; Ono: Honoraria, Research Funding; Pfizer: Research Funding; Symbio: Honoraria, Research Funding; Allergan Japan: Honoraria; FUJI FILM Toyama Chemical: Honoraria; MSD: Research Funding; Janssen: Honoraria, Research Funding; Incyte: Research Funding; Genmab: Honoraria, Research Funding; Chugai: Honoraria, Research Funding; Beigene: Research Funding; Bayer: Research Funding; AstraZeneca: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Yakult: Research Funding; Takeda Pharmaceutical: Honoraria, Research Funding; Kyowa Kirin: Honoraria, Research Funding; HUYA Bioscience International: Research Funding; Eisai: Honoraria, Research Funding; Daiichi Sankyo: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Terui: Ono Pharmaceutical: Speakers Bureau; MSD: Speakers Bureau; Janssen: Speakers Bureau; Esai: Speakers Bureau; Chugai Pharmaceutical: Speakers Bureau; Celgene: Speakers Bureau; AbbVie: Speakers Bureau; Takeda Pharmaceutical: Speakers Bureau. Ando: Astellas Pharma: Honoraria; Celgene: Honoraria; Chugai Pharmaceutical: Research Funding; Kyowa Kirin: Research Funding; Novartis: Honoraria; Takeda Pharmaceutical: Research Funding. Suehiro: Otsuka Pharmaceutical: Research Funding; Ono Pharmaceutical: Research Funding; Novartis: Research Funding; Nippon Shinyaku: Honoraria; Kyowa Kirin: Honoraria, Research Funding; Incyte: Research Funding; Eisai: Honoraria, Research Funding; Chugai Pharmaceutical: Honoraria, Research Funding; Celgene: Research Funding; Bristol-Myers Squibb: Honoraria; Bayer: Research Funding; Amgen BioPharma: Research Funding; Pfizer: Research Funding. Nagahama: Solasia Pharma: Current Employment, Current equity holder in publicly-traded company. Sonehara: Solasia Pharma: Current Employment, Current equity holder in publicly-traded company. Nagai: Ono Pharmaceutical: Honoraria; Sanofi: Honoraria; Sumitomo Dainippon Pharma: Honoraria; SymBio Pharmaceuticals: Honoraria, Research Funding; Takeda Pharmaceutical: Honoraria, Research Funding; Zenyaku Kogyo: Research Funding; Novartis: Honoraria; Nippon Shinyaku: Research Funding; Mundipharma: Honoraria, Research Funding; Kyowa Kirin: Research Funding; Janssen: Honoraria, Research Funding; Eisai: Honoraria, Research Funding; Chugai Pharmaceutical: Honoraria, Research Funding; Chordia Therapeutics: Honoraria; Celgene: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Bayer: Research Funding; AstraZeneca: Honoraria, Research Funding; AbbVie: Research Funding. Tien: Novartis: Honoraria; Celgene: Honoraria, Research Funding; AbbVie: Honoraria. Tobinai: Ono Pharmaceutical: Consultancy, Honoraria; Solasia Pharma: Honoraria; Mundipharma: Consultancy, Honoraria; Kyowa Kirin: Honoraria; HUYA Bioscience International: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Eisai: Honoraria; Chugai Pharmaceutical: Honoraria; Celgene: Consultancy, Honoraria; Takeda Pharmaceutical: Consultancy, Honoraria; Zenyaku Kogyo: Consultancy, Honoraria; Yakult: Honoraria. OffLabel Disclosure: Darinaparsin is an investigational product that is not approved in any country/region in the world.